Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDHeron Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | -$0.02 | -$0.01 | -$0.02 |
| Q2 2025 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q3 2025 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q4 2025 | 1 | -$0.00 | -$0.00 | -$0.00 |
Heron Therapeutics, Inc. Earnings Date And Information
Heron Therapeutics, Inc. last posted its earnings results on Thursday, February 27th, 2025. The company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of $-0.03 by $0.05. The company had revenue of 40.78 M for the quarter and had revenue of 144.29 M for the year. Heron Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.0891 diluted earnings per share) and currently has a price-to-earnings ratio of -27.18. Heron Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based on prior year's report dates.
Heron Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/27/2025 | Q4 2024 | -$0.03 | $0.02 | 0.05 | $37.29 M | $40.78 M |
| 11/12/2024 | Q3 2024 | -$0.03 | -$0.03 | -0 | $36.77 M | $42.27 M |
| 08/06/2024 | Q2 2024 | -$0.04 | -$0.06 | -0.02 | $36.09 M | $36.02 M |
| 05/07/2024 | Q1 2024 | -$0.08 | -$0.02 | 0.06 | N/A | $34.67 M |
| 03/12/2024 | Q4 2023 | -$0.15 | -$0.07 | 0.08 | $31.23 M | $34.23 M |
| 09/29/2023 | Q3 2023 | N/A | -$0.17 | N/A | $32.65 M | $31.43 M |
| 08/14/2023 | Q2 2023 | -$0.23 | -$0.35 | -0.12 | $31.70 M | $31.76 M |
| 05/11/2023 | Q1 2023 | -$0.17 | -$0.27 | -0.1 | N/A | $29.62 M |
| 03/29/2023 | Q4 2022 | N/A | -$0.23 | N/A | N/A | $30.03 M |
| 11/08/2022 | Q3 2022 | -$0.39 | -$0.38 | 0.01 | $26.96 M | $26.56 M |
| 08/09/2022 | Q2 2022 | -$0.50 | -$0.62 | -0.12 | $24.55 M | $27.63 M |
| 05/09/2022 | Q1 2022 | -$0.45 | -$0.64 | -0.19 | N/A | $23.46 M |
| 02/28/2022 | Q4 2021 | -$0.59 | -$0.54 | 0.05 | N/A | $20.66 M |
| 11/03/2021 | Q3 2021 | -$0.60 | -$0.51 | 0.09 | $25.52 M | $23.23 M |
| 08/09/2021 | Q2 2021 | -$0.59 | -$0.62 | -0.03 | $29.45 M | $22.44 M |
| 05/10/2021 | Q1 2021 | -$0.57 | -$0.58 | -0.01 | N/A | $20.02 M |
| 02/24/2021 | Q4 2020 | -$0.68 | -$0.68 | 0 | N/A | $20.61 M |
| 11/05/2020 | Q3 2020 | -$0.65 | -$0.64 | 0.01 | $17.17 M | $19.97 M |
| 08/05/2020 | Q2 2020 | -$0.59 | -$0.61 | -0.02 | $19.81 M | $22.67 M |
| 05/06/2020 | Q1 2020 | -$0.63 | -$0.57 | 0.06 | N/A | $25.40 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Heron Therapeutics, Inc. Earnings: FAQ's
Heron Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based offlast year's report dates.
In the previous quarter, Heron Therapeutics, Inc. (:HRTX) reported $0.02 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.03 by $0.05.
The conference call for Heron Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Heron Therapeutics, Inc.'s latest earnings report can be read online.
Heron Therapeutics, Inc. (:HRTX) has a recorded annual revenue of $144.29 M.
Heron Therapeutics, Inc. (:HRTX) has a recorded net income of $-13,580,000.Heron Therapeutics, Inc. has generated $-0.0891 earnings per share over the last four quarters.
Heron Therapeutics, Inc. (:HRTX) has a price-to-earnings ratio of -27.18 and price/earnings-to-growth ratio is -0.54.